Publications 2015

Laboratory biomarkers and frailty: presentation of the frailomic initiative
G. Lippi, P. Jansen-Duerr, J. Viña, A. Durrance-Bagale, I. Abugessaisa, D. Gomez-Cabrero, J. Tegnér, J. Grillari, J. Erusalimsky, A. Sinclair, L. Rodriguez-Manãs, FRAILOMIC consortium
Clinical Chemistry and Laboratory Medicine, 1;53(10): e253-5 2015
G. Lippi, P. Jansen-Duerr, J. Viña, A. Durrance-Bagale, I. Abugessaisa, D. Gomez-Cabrero, J. Tegnér, J. Grillari, J. Erusalimsky, A. Sinclair, L. Rodriguez-Manãs, FRAILOMIC consortium
Ageing; Biomarkers; Frailty; Sarcopenia
2015
​Frailty is traditionally defined as a specific geriatric syndrome characterized by increased vulnerability to unfavorable outcomes, such as falls, disability, hospitalization and overall mortality, which is a result of the impairment of manifold and interrelating biological pathways, ultimately leading to decreased homoeostatic reserve and lower resistance to stressor events, such as therapy or infections . Due to an increasing trend toward ageing of the population (the percentage of people aged ≥ 65 years is projected to increase by 20% in Europe by 2060), frailty will soon emerge as a serious and increasingly important global health burden.



DOI: https://doi.org/10.1515/cclm-2015-0147